header
Image from OpenLibrary

Prognostic value of early introduction of second line chemotherapy in patients with diffuse large B cell lymphoma : Prospective study / Mennat Allah Mahmoud Mohammed Abdelradi ; Supervised Hamdy Mohammed Zawam , Emad Mahmoud Hamada , Yasser Baghdady

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Mennat Allah Mahmoud Mohammed Abdelradi , 2015Description: 124 P. : facsimiles ; 25cmOther title:
  • الفائدة العلاجية للاستخدام المبكر للخط الثانى فى العلاج الكيميائى فى حالات سرطان الغدد الليمفاوية [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Oncology - Clinical Summary: DLBCL is the commonest type of lymphoma. The mainstay of treatment is chemotherapy. Earlier response is associated with better survival. Anthracyclines are effective but cardiotoxic. This is a randomized pilot trial of 50 adult patients with DLBCL conducted at Kasr Alainy oncology department, ages 18 years-65 years) pathologically proven as DLBCL stages I bulky - IV according to Ann Arbor classification, ECOG Performance status < 3. Patients were treated with standard dose 3 weekly R - CHOP for 3 cycles. Those achieved partial remission were randomized to either continue R - CHOP or to shift to ESHAP + / - rituximab. All patients were randomized also to either receive prophylactic carvidolol plus enalapril or not to receive them. Troponin I, echocardiography chest, abdomen and pelvic CT scan were used to re - assess the patients. 50 patients were enrolled between May 2013 and September 2014. median age was 51 years. Better outcome with non shift group ( RR = 90.9 % Vs 66.67%). The 12 month DFS in the continue group was 75 % while in ESHAP group was 58% which is statistically significant (p value = 0.049). The 12 month OS was 100 % in the continue group versus 68 % in the ESHAP group which is statistically significant (p value = 0.003). No early cardiotoxicity was encountered in the whole group. These results should be confirmed on larger scale studies
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.23.Ph.D.2015.Me.P (Browse shelf(Opens below)) Not for loan 01010110069098000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.23.Ph.D.2015.Me.P (Browse shelf(Opens below)) 69098.CD Not for loan 01020110069098000

Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Oncology - Clinical

DLBCL is the commonest type of lymphoma. The mainstay of treatment is chemotherapy. Earlier response is associated with better survival. Anthracyclines are effective but cardiotoxic. This is a randomized pilot trial of 50 adult patients with DLBCL conducted at Kasr Alainy oncology department, ages 18 years-65 years) pathologically proven as DLBCL stages I bulky - IV according to Ann Arbor classification, ECOG Performance status < 3. Patients were treated with standard dose 3 weekly R - CHOP for 3 cycles. Those achieved partial remission were randomized to either continue R - CHOP or to shift to ESHAP + / - rituximab. All patients were randomized also to either receive prophylactic carvidolol plus enalapril or not to receive them. Troponin I, echocardiography chest, abdomen and pelvic CT scan were used to re - assess the patients. 50 patients were enrolled between May 2013 and September 2014. median age was 51 years. Better outcome with non shift group ( RR = 90.9 % Vs 66.67%). The 12 month DFS in the continue group was 75 % while in ESHAP group was 58% which is statistically significant (p value = 0.049). The 12 month OS was 100 % in the continue group versus 68 % in the ESHAP group which is statistically significant (p value = 0.003). No early cardiotoxicity was encountered in the whole group. These results should be confirmed on larger scale studies

Issued also as CD

There are no comments on this title.

to post a comment.